MedTrace Logo

An EAP Treatment Protocol of Zipalertinib

NCT07601399 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-06-11

No results posted yet for this study

Summary

"Only licensed physicians may submit an email inquiry/question about Taiho's Zipalertinib Expanded Access Program via email ([email protected]). If you are a patient or caregiver, do not email Parexel or Taiho. Please talk to your physician. Do not share any patient Personally Identifiable Information with Parexel."

The objective of the study is to provide access to zipalertinib to patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations whose disease has progressed on or after platinum-based chemotherapy with or without amivantamab.

Conditions

Interventions

DRUG

Zipalertinib

Participants will self-administer 100 mg dose, orally, twice daily (BID), continuously in 28-day cycles.

Sponsors & Collaborators

  • Taiho Oncology, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07601399 on ClinicalTrials.gov